Regeneron (REGN), Sanofi (SNY) Report Publication of Results from Two Positive Phase 3 Trials of Dupixent (dupilumab) in Severe Chronic Rhinosinusitis with Nasal Polyps
Tweet Send to a Friend
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (NYSE: SNY) today announced that The Lancet has published detailed positive results from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
